Eris Lifesciences Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI depositories regulations for the quarter ended 31st March 2026.

Regulatory Compliance Filing

The pharmaceutical company filed its certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 on 10th April 2026. The submission was made to both BSE Limited and National Stock Exchange of India Limited, where the company's shares are listed.

Registrar Confirmation

The compliance certificate was prepared and confirmed by MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, which serves as the company's Registrar and Share Transfer Agent (RTA). The registrar provided comprehensive confirmation regarding the handling of dematerialized securities during the quarter.

Certificate Confirmations

MUFG Intime India confirmed several key compliance aspects for the quarter ended 31st March 2026:

• All securities received from depository participants for dematerialization were confirmed to depositories
• Securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were properly confirmed or rejected
• Physical certificates were mutilated and cancelled after due verification by depository participants
• Depository names were substituted in the register of members as registered owners within prescribed timelines

Corporate Communication

The filing was signed by Milind Talegaonkar, Company Secretary and Compliance Officer of Eris Lifesciences Limited, holding ICSI Membership No. A26493. The certificate was also copied to National Securities Depository Limited and Central Depository Services (India) Limited, the two main depositories in India.

Company Information

Eris Lifesciences Limited operates from its registered and corporate office located at Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054. The company maintains its compliance obligations through regular filings with stock exchanges and regulatory authorities.

Eris Lifesciences Limited has successfully completed its acquisition of the probiotics business from Velbiom Probiotics Private Limited, the pharmaceutical company announced to stock exchanges on March 31, 2026. The transaction closure follows the company's earlier intimation to exchanges dated March 20, 2026.

Transaction Completion Details

The acquisition has been completed to the extent and in the manner outlined in the company's original March 20, 2026 communication to the exchanges. The regulatory filing confirms that all necessary procedures for the transaction closure have been fulfilled.

Regulatory Compliance

The update was filed under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations. Company Secretary & Compliance Officer Milind Talegaonkar (Membership No: A26493) digitally signed the filing on March 31, 2026.

Exchange Communication

Eris Lifesciences communicated the transaction completion to both major Indian stock exchanges:

• BSE Limited (Security Code: 540596)
• National Stock Exchange of India Limited (Symbol: ERIS)

The company emphasized that this information is provided for the exchanges' information and record purposes, ensuring transparency with stakeholders regarding the completed acquisition.